联合雾化吸入治疗慢性阻塞性肺疾病急性加重期的疗效

Clinical effects of nebulized budesonide combined with ipratropine and terbutaline in treatment of acute exacerbations of chronic obstructive pulmonary disease

目的观察布地奈德、异丙托溴胺及特布他林联合雾化吸入治疗慢性阻塞性肺疾病急性加重期（AECOPD）的临床疗效。方法将76例AECOPD患者随机分为对照组和观察组，每组38例，对照组给予抗感染、平喘、祛痰等常规治疗；观察组在对照组基础上加用布地奈德、异丙托溴胺和特布他林联合雾化吸入治疗，观察两组治疗后疗效。结果对照组和观察组总有效率分别为68．42％和94．74％，差异有统计学意义（P〈0．05）；两组患者血气分析、肺功能指标均较治疗前明显改善，且观察组改善程度均显著优于对照组（P〈0．05）。结论布地奈德、异丙托溴胺及特布他林联合雾化吸入治疗AECOPD可显著改善肺功能和临床症状，且操作简便，不良反应少，值得临床推广应用。

Objective To observe the clinical effects of nebulized budesonide combined with ipratropine and terbutatine in treatment of acute exacerbations of chronic obstructive pulmonary disease（AECOPD）. Methods Seventy-six patients with AECOPD were randomly divided into the control group and observation group, with 38 cases in each group. Patients in control group were re-ceived conventional anti-infection, repress asthma and expectorant treatment, while patients in observation group were received budesonide, ipratropine and terbutaline on the basis of conventional treatment. Results The effec- tive rate of control and observation group were 68.42%, 94. 74% , there was statistically significant difference between the two groups （ P 〈 0.05 ）. Blood gas analysis and pulmonary function index of the two groups were improved significantly after treatment, and the improvement of blood gas and pulmonary function in observation group were more significantly after treatment （ P 〈 0.05 ）. Conclusions The therapy of inhaling nebulized budesonide combined with ipratropine and terbutaline can improve pulmona- ry function and clinical symptoms significantly, and is easy to use, it is safe and worthy of being extended in clinical.